Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



GSK submits multiple myeloma treatment for approval to the US regulator

November 28, 2024
GSK, a leading pharmaceutical company, has recently submitted its groundbreaking treatment for multiple myeloma to the US regulator for approval. This treatment has shown promising results in clinical trials, offering new hope for patients suffering from this rare form of cancer. Experts from Stocks Prognosis recommend investors to consider buying GSK shares, as the approval of this treatment could significantly boost the company's stock performance in the future.

Find out how the GSK PLC rate is expected to change

Get Forecast for GSK

Investor opinions & comments:

This is great news! I'm glad GSK is making progress in treating multiple myeloma
— from AshleyMartinez at 12-01-2024 06:53
The stock market could definitely take notice of this groundbreaking treatment. Exciting times for GSK!
— from GrowthGiselle at 12-01-2024 04:41
I'm excited to see how this new treatment could improve the lives of those with multiple myeloma
— from WealthyWes at 11-30-2024 20:41
Is GSK the only company working on a treatment for multiple myeloma? I'm curious about the competition
— from FinanceFiona at 11-30-2024 01:54
I hope the approval process is thorough. We need to ensure the safety and effectiveness of this treatment
— from WealthyWes at 11-29-2024 22:35
How effective is this treatment compared to existing options? I'd like to see more data
— from ZoeRoss at 11-29-2024 04:51
I have faith in GSK's research and development capabilities. I believe this treatment has great potential
— from FinanceFlo at 11-29-2024 01:31
I hope this treatment gets approved soon. It could really make a difference for patients
— from DanielTaylor at 11-28-2024 17:24
This is fantastic news! GSK's dedication to finding new treatments is commendable
— from CashCathy at 11-28-2024 07:58
If you want to leave a comment, then you need Login or Register





Other news for GSK

GSKJune 2, 2025QuantWave Delivers 7.39% Profit with Successful GSK PLC Stock Price Target Forecast  ~2 min.

On March 21, 2025, QuantWave, the automated forecasting platform, signaled a long position for GSK PLC at a price of 38.79 $. Today, on June 2, 2025, the stock reached the predicted target price of 41....

GSKJune 2, 2025QuantWave Hits Price Target Forecast for GSK PLC, Yielding 8.78% Profit  ~1 min.

QuantWave, the automated forecasting platform, successfully achieved its price target forecast for GSK PLC, resulting in a profit of 8.78%....

GSKJune 2, 2025QuantWave Achieves GSK PLC Price Target Forecast with 6.93% Profit  ~1 min.

QuantWave, the leading automated forecasting platform, has successfully hit the price target forecast for GSK PLC, resulting in a profitable trade with a 6.93% gain....

GSKJune 2, 2025QuantWave Achieves 8.39% Profit Target Forecast for GSK PLC Stock  ~1 min.

QuantWave, an automated forecasting platform, has successfully hit a price target forecast for the stock of GSK PLC, resulting in a profit of 8.39%....

GSKJune 2, 2025QuantWave Achieves 11.28% Profit Target Forecast for GSK PLC  ~1 min.

QuantWave, the automated forecasting platform, successfully predicted a long position for GSK PLC on April 1, 2025, when the stock was trading at $37.44....



Related news

VRTXJanuary 12, 2025Vertex Pharmaceuticals Incorporated Faces Setbacks in Clinical Trials  ~1 min.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares experienced a slide recently due to setbacks in its clinical trials....

PFENovember 21, 2024Pfizer Inc. Introduces Groundbreaking Immunotherapy Treatment, Boosting Confidence in PFE Stock  ~2 min.

Pfizer Inc., a leading pharmaceutical company, has announced the development of a groundbreaking immunotherapy treatment that could revolutionize cancer treatment....

PFEFebruary 28, 2025Pfizer Inc. PFE Announces Groundbreaking Cancer Treatment: Here is What You Should Know  ~2 min.

Pfizer Inc. PFE has recently made a groundbreaking announcement in the field of cancer treatment, attracting significant attention from investors....

REGNJanuary 1, 2025Regeneron Pharmaceuticals, Inc.: Groundbreaking Discoveries in Drug Development  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has made remarkable progress in the field of drug development, delighting its investors with a decent 89% return over the past five years....

BMYJanuary 25, 2025Is Bristol-Myers Squibb Company the New Game-Changer in the Pharmaceutical Industry?  ~2 min.

Renowned investor Jim Cramer has recently touted Bristol-Myers Squibb Company (BMY) as the one that everyone in the industry is talking about....